Background: Metabolic disorders such as diabetes, hypertension, and hyperlipidemia represent interconnected global health challenges with escalating prevalence. Despite advances in pharmacotherapy, conventional treatments often fail to address the multifactorial nature of these conditions and pose risks of side effects. Berberis vulgaris (barberry), a medicinal plant enriched with berberine and other bioactive compounds, has emerged as a promising alternative due to its multi-targeted therapeutic potential. This review explores the role of B. vulgaris in the prevention and treatment of metabolic disorders, highlighting its innovative mechanisms and clinical applicability. Methods: A systematic review was conducted to analysed preclinical and clinical studies on B. vulgaris. Phytochemical profiling using advanced techniques like HPLC and GC-MS was assessed, along with pharmacological evaluations of its anti-diabetic, anti-hypertensive, and anti-hyperlipidemic properties. Mechanistic pathways, including AMPK activation, RAAS modulation, and HMG-CoA reductase inhibition, were explored. Toxicity studies and emerging formulation strategies, such as nanomedicines and functional foods, were reviewed to evaluate safety and efficacy. Results: B. vulgaris exhibits potent therapeutic activity by lowering blood glucose, regulating blood pressure, and reducing lipid levels. Recent evidence also highlights its role in gut microbiota modulation, oxidative stress reduction, and anti-inflammatory action, offering a systemic approach to metabolic regulation. Advanced formulations, including barberry-based nutraceuticals, have enhanced bioavailability and therapeutic outcomes in recent studies. Conclusion: Berberis vulgaris offers an innovative, nature-inspired solution for addressing metabolic disorders. While its potential is evident, further large-scale clinical trials and formulation standardization are imperative to integrate it into mainstream healthcare.